The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.
 
Bartosz Chmielowski
Consulting or Advisory Role - Delcath Systems; Genentech; IDEAYA Biosciences; Instil Bio; Nektar; Novartis
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Kinnate Biopharma (Inst); Macrogenics (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Instil Bio
 
Saravut John Weroha
Research Funding - Genentech; KIYATEC; Novartis; Tesaro
Patents, Royalties, Other Intellectual Property - Kiyatec; Mayo Clinic Ventures Ovarian Cancer PDX Models
Travel, Accommodations, Expenses - Merck
(OPTIONAL) Uncompensated Relationships - KIYATEC
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - AstraZeneca; Eisai; IgM Biosciences
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Deborah Blythe Doroshow
Consulting or Advisory Role - AstraZeneca; Atheneum; Dedham Group; GlobalData; Mirati Therapeutics; MJH Life Sciences
Travel, Accommodations, Expenses - MJH Life Sciences
Other Relationship - Bristol Myers Squibb Foundation; Conquer Cancer Foundation
 
Frances Valdes
Honoraria - Adverum (I); Allergan (I); BVI (I); EyePoint Pharmaceuticals (I); Genentech (I); NGM Biopharmaceuticals (I); Novartis (I); Valeant Pharmaceuticals International (I)
Research Funding - Atreca (Inst); Hibercell (Inst); Merck (Inst); Molecular Templates (Inst); Orinove (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Apros Therapeutics; Arcus Biosciences; Ascendis Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals; Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; I-Mab (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); Molecular Templates (Inst); MT Group (Inst); NextCure (Inst); Nuvation Bio (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Alejandro Recio-Boiles
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; insmed; ipsen; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); pfizer (Inst); PsiOxus Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Yan Xing
No Relationships to Disclose
 
Sudha Khurana
Employment - Atreca; Genentech/Roche
Stock and Other Ownership Interests - 23andMe (I); Akebia Therapeutics (I); Alaunos Therapeutics (I); BioNano Genomics (I); Compugen (I); Evogene (I); Invitae (I); Natera (I); Pacific Biosciences (I); Personalis (I); Rigel (I); Sorrento Therapeutics (I); Syros Pharmaceuticals (I); Tenet Healthcare (I); Tonix Pharmaceuticals (I); Verastem (I); Viatris (I)
 
Philippe Bishop
Employment - Atreca; Clover Biopharmaceuticals
Leadership - Atreca; Clover Biopharmaceuticals
Stock and Other Ownership Interests - Atreca; Clover Biopharmaceuticals
 
Steven J. Isakoff
Employment - Merus (I)
Stock and Other Ownership Interests - Merus NV (I)
Consulting or Advisory Role - Paxman
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Merck (Inst); OncoPep (Inst); Outcomes4Me (Inst)
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Rafael Pharmaceuticals
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; HalioDx; Merus NV
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences; Merus NV